StockGlow

Abeona Therapeutics Inc. (ABEO)

Develops gene therapies to treat inherited genetic diseases and blindness.

$6.02-0.02%Healthcare
Compare ABEO with
StockGlow Score
89
Bullish
BearishBullish
1 year ago-7.2%

The outlook

ABEO trades at $6.02, sitting above both its 50- and 200-day moving averages in the middle of its 52-week range. Analyst consensus strongly favors the stock, with an average price target implying significant upside from current levels. The trailing P/E of 6.3 suggests a relatively low valuation multiple compared to recent earnings.

What’s behind the score

Analyst consensusStrong Buy — 1.0 avg of 7 analysts
Price trendAbove its 50- & 200-day averages
52-week range57% of the way from its 52-week low to high
Price targetAvg target +227% vs current price

Analyst price target

~12-month · 7 analysts
$19.71average target+227.5% vs now
Now $6.02
Low $14.00High $28.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$343.1M
52-wk high
$7.54
52-wk low
$4.00
50-day avg
$5.97
200-day avg
$5.30
Trailing P/E
6.3

Similar stocks

MREOMereo BioPharma Group plc$0.31+2.42%AKBAAkebia Therapeutics, Inc.$1.27-0.78%ALDXAldeyra Therapeutics, Inc.$1.58-0.32%ABUSArbutus Biopharma Corporation$4.41+0.00%VSTMVerastem, Inc.$6.23+2.47%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy